CN107998108A - A kind of composite material using degradable metal Grain size controlling insoluble drug release - Google Patents
A kind of composite material using degradable metal Grain size controlling insoluble drug release Download PDFInfo
- Publication number
- CN107998108A CN107998108A CN201810068594.8A CN201810068594A CN107998108A CN 107998108 A CN107998108 A CN 107998108A CN 201810068594 A CN201810068594 A CN 201810068594A CN 107998108 A CN107998108 A CN 107998108A
- Authority
- CN
- China
- Prior art keywords
- composite material
- degradable
- degradable metal
- medicine
- high molecular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of using composite material of degradable metal Grain size controlling insoluble drug release and preparation method thereof, belong to biology medical material technical field.The composite material is by high molecular polymer, degradable metal particle and medicine three parts composition.The preparation of the composite material be using three kinds of materials described in claim 1, by high molecular polymer, degradable metal particle and medicine is compound is prepared.The present invention is that a kind of novel degradable metal particle/high molecular polymer carries medicine composite material, the rate of release of medicine in composite material can be regulated and controled by the quantity and/or size and/or species of degradable metal particle, there is good biocompatibility and biodegradability again, get a good chance of being used widely in medicine controlled releasing field.
Description
Technical field
The invention belongs to biology medical material technical field.It more particularly relates to a kind of utilize degradable gold
Composite material of metal particles Drug controlled release and preparation method thereof.
Background technology
High molecular polymer has broad application prospects as a kind of good pharmaceutical carrier in disease treatment field.
By the way that by drug encapsulation, in wherein, medicine can be discharged with slow speed, not only extend drug effect, improve the life of medicine
Thing availability, and administration frequency is reduced, significantly reduce painful caused by multiple dosing and patient.To various disease
For, it is necessary to drug release rate be also not quite similar, it is unfavorable that too fast or excessively slow insoluble drug release can all cause disease treatment
Influence.At this moment, it is necessary to which polymer adapts to a variety of illnesss with adjustable medicine sustained and controlled release ability.It is but common
Drug-carrying polymer it is exactly serious there is burst release, the problems such as drug release rate is uncontrollable, these problems greatly limit
Its application as pharmaceutical carrier.In recent years, in order to overcome these problems, the load medicine that can largely adjust drug release rate gathers
Compound has been designed out.
The mode of insoluble drug release mainly has two kinds in polymer：1st, the degraded of polymer, 2, the diffusion of medicine.All polymerizations
The slow-releasing and controlled-releasing action of thing is realized by regulating and controlling both factors in itself.At present, setting for controlled release drug-carrying polymer is delayed
Meter thinking has following several：1st, choose with different degradation rates polymer be used as pharmaceutical carrier, 2, preparation there is shell-core knot
Polymer (porous nuclear shell structure nano fibers of the such as Xu Lan, Wang Yaru, Zhao Jianghui and preparation method thereof of structure
.CN107059157A,2017；The preparation method .CN 101773479A of the shell-core double-layer microspheres such as Jin Tuo, Yuan Weien, Wu Fei,
2010), 3, preparing can be to external condition, such as temperature, polymer (Zhao Yuanjin, Zhang Bin, Gu Xiao that illumination and pH etc. respond
Know a kind of Thermo-sensitive encoding drug control-release microsphere carriers of and preparation method thereof .CN 106214644A, 2016；Zhu Limin, Sang Qing
Green grass or young crops, a kind of application of the double drug-loading fibre stents of the coaxial polylactic acid caprolactone PLCL/ gelatin of pH sensitiveness of Wu Huan woodss
.CN107096066A,2017).But the degradation rate for changing polymer is difficult to the release of accuracy controlling medicine；And shell-caryogram
And it is temperature sensitive, although Photosensitive polymer can be by controlling the diffusion of medicine to reach preferable medicine controlled releasing ability, it is made
Standby process is again excessively complicated, these deficiencies greatly limit the application of several drug-carrying polymers of the above.
In past decades, degradable metal is extensively studied, and the metal of such as iron, magnesium, zinc etc is proved to have
There are good biocompatibility and biodegradable characteristics, be widely used in the fields such as intravascular stent, plastic surgery.Mesh
Before, from the point of view of the situation of literature survey, rarely have and degradable metal particle is coated in polymer for Drug controlled release
Report.
The content of the invention
In view of the deficiencies of the prior art, it is of the invention provide it is a kind of using degradable metal Grain size controlling insoluble drug release
Composite material and preparation method thereof, its preparation process is simple, favorable repeatability, and the characteristic of water degraded is met using degradable metal,
Make metallic particles after being coated in polymer, can slowly degrade in using water as the environment of medium, in composite material table
Face and it is internally formed many small holes, the connectivity being stepped up inside and outside composite material, and then influence medicine in composite material
Release., can accurately controlled material surface by varying the quantity and/or size and/or species of degradable metal particle
With the synthesis speed and pore quantity of inner void, and then control composite material in drug release rate purpose.
The high molecular polymer is degradable high polymer.Degradable high polymer is as pharmaceutical carrier
When, mainly pass through the degraded slow releasing pharmaceutical of polymer.The release of medicine had been both after degradable metal particle is added, in composite material
Influenced by degradable high polymer slow releasing function, and influenced by the effect of degradable metal granular controlled release.
The material and method of controlled release are not carried out to medicine in non-degradable high molecular polymer in the prior art, especially
Ground, the composite material in the application can be adapted for non-degradable high molecular polymer.High molecular polymer can be not
Degradable high polymer.When non-degradable high molecular polymer is as pharmaceutical carrier, due to polymer can not drop in itself
Xie Xing, the slow releasing function there is no depolymerization to insoluble drug release.After degradable metal particle is added, in composite material
Insoluble drug release is only influenced by the effect of degradable metal granular controlled release.
The degradable metal particle refers to the metallic particles that can be degraded in using water as the environment of medium.
The degradable metal particle specifically includes iron particle, magnesium granules or zinc particle.Wherein, iron particle degradation speed is most
Slowly, magnesium granules degradation speed is most fast, and zinc pellet degradation speed is between iron particle and magnesium granules.
Medicine is released through the quantity and/or size and/or species for adjusting degradable metal particle in the composite material
It is controlled.
The form of the composite material can be microballoon composite material, film composite material, prop composite etc..
It is a kind of to be answered using degradable metal particle/high molecular polymer microballoon of degradable metal Grain size controlling insoluble drug release
The preparation method of condensation material, it is characterised in that the preparation of the microballoon composite material be first by high molecular polymer, it is degradable
Metallic particles and medicine are sufficiently mixed, and then high speed emulsion dispersion forms under the action of surfactant.Specifically include following
Each step：
(1) high molecular polymers such as polylactic acid, Poly(D,L-lactide-co-glycolide are dissolved in CH2Cl2、CHCl3、
CH3COOC2H5Deng in organic solvent, certain density solution is made into；
(2) degradable metal particle is added in the solution that the above-mentioned first step obtains, is carried out in the state of magnetic agitation
Mixing, makes metallic particles be uniformly dispersed wherein；
(3) different medicine process for dispersing is selected according to the difference of package-contained medicine in microballoon.If medicine is water-insoluble
Medicine, then should add medicine in the solution obtained by above-mentioned second step in the case of magnetic agitation, medicine is disperseed wherein
Uniformly, oil phase is obtained；If medicine is water soluble drug, should be soluble in water by medicine first, obtain the aqueous solution of medicine, then by this
Aqueous solution adds in the solution obtained by above-mentioned second step and forms mixed solution, this mixed solution is placed in ultrasound 0.5~2 in ice bath
Minute is emulsified for 0.5~2 minute with high-speed homogenization machine high-speed stirred, obtains W/O (Water-In-Oil) colostrum；
(4) oil phase or W/O (Water-In-Oil) colostrum that obtain above-mentioned 3rd step are poured slowly into the surface-active of high-speed stirred
In agent solution, mixing speed is 500~20,000 rev/min, obtains O/W (oil-in-water) lotions or W/O/W (W/O/W) is multiple
Breast, and continue stirring 3~24 it is small when, it is therefore an objective to remove the organic solvent in lotion；
(5) lotion for eliminating organic solvent that above-mentioned 4th step obtains is placed in centrifugation in centrifuge tube and removes supernatant, will be heavy
After shallow lake washs 3~5 times repeatedly with distilled water, freeze overnight in -80 DEG C of refrigerators is placed in；Fully after freezing, precipitation is transferred to cold
When freeze-drying 24~48 is small in lyophilizer；Finally obtain the degradable gold using degradable metal Grain size controlling insoluble drug release
Metal particles/high molecular polymer microballoon composite material.
It is a kind of compound using degradable metal particle/polymer membrane of degradable metal Grain size controlling insoluble drug release
The preparation method of material, it is characterised in that the preparation process of the film composite material be first by high molecular polymer, it is degradable
Metallic particles and medicine are sufficiently mixed obtained mixed liquor, and then this mixed liquor is cast in culture dish, and are freeze-dried, then use
Tabletting machine is made.Specifically include following each step：
(1) high molecular polymers such as polylactic acid, Poly(D,L-lactide-co-glycolide are dissolved in CH2Cl2、CHCl3、
CH3COOC2H5Deng in organic solvent, certain density solution is made into；
(2) degradable metal particle and medicine are added in the solution that the above-mentioned first step obtains, in the state of magnetic agitation
Under mixed, degradable metal particle and medicine is uniformly dispersed wherein；
(3) solution that above-mentioned second step obtains is cast in culture dish, to being placed in freeze overnight in -80 DEG C of refrigerators；Fill
After point freezing, be transferred into freeze drier freeze-drying 24~48 it is small when；
(4) flaky composite material obtained after above-mentioned 3rd step is freezed finally obtains utilization as tabletting in tablet press machine
Degradable metal particle/polymer membrane composite material of degradable metal Grain size controlling insoluble drug release.
It is a kind of to be answered using degradable metal particle/high molecular polymer stent of degradable metal Grain size controlling insoluble drug release
The preparation method of condensation material, it is characterised in that the preparation of the prop composite be first by high molecular polymer, it is degradable
Metallic particles and medicine are sufficiently mixed obtained mixed liquor, and then this mixed liquor is cast in polystyrene mould, then low temperature cold
But, freeze-drying forms.Specifically include the following steps：
(1) that the high molecular polymers such as polylactic acid, Poly(D,L-lactide-co-glycolide are dissolved in 1,4- dioxane etc. is organic
In solvent, certain density solution is made into；
(2) degradable metal particle and medicine are added in the solution that the above-mentioned first step obtains, uses magnetic agitation or super
Sound is uniformly mixed；
(3) mixed solution that above-mentioned second step is matched somebody with somebody is cast in tubulose polystyrene mould, is placed in -20 DEG C of refrigerators
In overnight；
(4) by sufficiently chilled composite material be placed in freeze drier freeze 48 it is small when, that is, be utilized degradable gold
Degradable metal particle/high molecular polymer prop composite of metal particles Drug controlled release.
Medicine is carried the beneficial effects of the invention are as follows the degradable metal particle obtained by the above method/high molecular polymer to answer
Condensation material has the advantages that very notable：
(1) preparation method of composite material is simple, easy to operate, and repeatability is high；
(2) by varying the quantity and/or size and/or species of the degradable metal particle being wrapped in composite material,
Can be with the drug release rate of accuracy controlling composite material；
(3) the obtained composite material of the present invention is either microballoon composite material, and can be film composite material, can be with
It is prop composite, thus answering for various different sizes and shapes can be optionally prepared according to the difference using position
Condensation material.
Therefore, the present invention is that a kind of novel degradable metal particle/high molecular polymer carries medicine composite material, Ji Nengtong
Quantity and/or size and/or the species of degradable metal particle are crossed to regulate and control the rate of release of medicine in composite material, and is had
Good biocompatibility and biodegradability, get a good chance of being used widely in medicine controlled releasing field.
Brief description of the drawings
Fig. 1 is the scanning electron of magnesium granules/poly (L-lactic acid) microballoon composite material prepared by embodiment 1 of the present invention
Microscope figure.Wherein, some circular configurations of the appearance of microsphere surface are exposed degradable magnesium particle.
Fig. 2 is magnesium granules/Poly(D,L-lactide-co-glycolide microballoon composite wood prepared by embodiment 5 of the present invention
The scanning electron microscope diagram of material.Wherein, some circular configurations of the appearance of microsphere surface are exposed degradable magnesium particle.
Fig. 3 is the photo figure of magnesium granules/poly (L-lactic acid) film composite material prepared by embodiment 6 of the present invention.
Fig. 4 is the external medicine of the different magnesium granules/poly (L-lactic acid) microballoon composite material of the content of magnesium of the invention prepared
Release figure.As it can be seen that in the case where magnesium granules size is identical, the rate of release of medicine adds with increasing for content of magnesium in microballoon
It hurry up.
Fig. 5 is magnesium granules/poly (L-lactic acid) microballoon composite material that the present invention selects prepared by different size of magnesium granules
Vitro drug release figure.As it can be seen that in the case where content of magnesium is identical, the rate of release of medicine subtracting with magnesium granules particle diameter in microballoon
It is small and accelerate.
Embodiment
For a better understanding of the present invention, with reference to the embodiment content that the present invention is further explained, but the present invention
Content is not limited solely to the following examples.
Embodiment 1：
0.2925g poly (L-lactic acid) is weighed, is dissolved in 5mL dichloromethane solvents, it is the molten of 58.5g/L to be configured to concentration
Liquid.After it is completely dissolved, then 0.0075g magnesium granules (9.67 ± 4.93 μm of average grain diameter) are accurately weighed, be added thereto and fill
Divide stirring, magnesium is dispersed in solution, obtain oil phase.25mg bovine serum albumins are weighed as model drug, be dissolved in 0.5mL go from
In sub- water, the solution that concentration is 50g/L is configured to, obtains inner aqueous phase.2.5g polyvinyl alcohol is weighed, is dissolved in 250mL deionized waters,
The solution that concentration is 10g/L is configured to, obtains outer aqueous phase.Inner aqueous phase is poured into oil phase, the Probe Ultrasonic Searching 30s under condition of ice bath,
Each ultrasound 2.5s pause 0.5s, obtain W/O (Water-In-Oil) colostrum.Outer aqueous phase is placed in high speed agitator again, with 550rpm's
Speed is stirred, and is instilled in the outer aqueous phase of high-speed stirred W/O (Water-In-Oil) colostrum dropwise with rubber head dropper, is obtained W/O/W (water
Bag Water-In-Oil) emulsion, continue stirring 5 it is small when, after dichloromethane completely volatilization after, centrifuge microballoon, then washed with distilled water
Wash 5 times, be placed in pre-freeze 12h in -80 DEG C of refrigerators, then be placed in freeze drier and be freeze-dried, it is micro- to obtain magnesium granules/poly (L-lactic acid)
Ball composite material.
Embodiment 2：
0.27g poly (L-lactic acid) is weighed, is dissolved in 5mL dichloromethane solvents, is configured to the solution that concentration is 54g/L.Treat
After it is completely dissolved, then 0.03g magnesium granules (9.67 ± 4.93 μm of average grain diameter) are accurately weighed, are added thereto and are sufficiently stirred,
Magnesium is dispersed in solution, obtain oil phase.25mg bovine serum albumins are weighed as model drug, are dissolved in 0.5mL deionized waters,
The solution that concentration is 50g/L is configured to, obtains inner aqueous phase.2.5g polyvinyl alcohol is weighed, is dissolved in 250mL deionized waters, is configured to
Concentration is the solution of 10g/L, obtains outer aqueous phase.Inner aqueous phase is poured into oil phase, the Probe Ultrasonic Searching 30s under condition of ice bath, it is super every time
Sound 2.5s pause 0.5s, obtain W/O (Water-In-Oil) colostrum.Outer aqueous phase is placed in high speed agitator again, with the speed of 550rpm into
Row stirring, W/O (Water-In-Oil) colostrum is instilled in the outer aqueous phase of high-speed stirred, obtain W/O/W (oil-in-water bags dropwise with rubber head dropper
Water) emulsion, continue stirring 5 it is small when, after dichloromethane completely volatilization after, centrifuge microballoon, then washed 5 times with distilled water,
Pre-freeze 12h in -80 DEG C of refrigerators is placed in, then is placed in freeze drier and is freeze-dried, it is compound to obtain magnesium granules/poly (L-lactic acid) microballoon
Material.
Embodiment 3：
0.2925g poly (L-lactic acid) is weighed, is dissolved in 5mL dichloromethane solvents, it is the molten of 58.5g/L to be configured to concentration
Liquid.After it is completely dissolved, then 0.0075g magnesium granules (31.02 ± 14.17 μm of average grain diameter) are accurately weighed, be added thereto simultaneously
It is sufficiently stirred, magnesium is dispersed in solution, obtains oil phase.25mg bovine serum albumins are weighed as model drug, 0.5mL is dissolved in and goes
In ionized water, the solution that concentration is 50g/L is configured to, obtains inner aqueous phase.2.5g polyvinyl alcohol is weighed, is dissolved in 250mL deionized waters
In, the solution that concentration is 10g/L is configured to, obtains outer aqueous phase.Inner aqueous phase is poured into oil phase, the Probe Ultrasonic Searching under condition of ice bath
30s, each ultrasound 2.5s pause 0.5s, obtains W/O (Water-In-Oil) colostrum.Outer aqueous phase is placed in high speed agitator again, with
The speed of 550rpm is stirred, and is instilled in the outer aqueous phase of high-speed stirred W/O (Water-In-Oil) colostrum dropwise with rubber head dropper, is obtained
W/O/W (W/O/W) emulsion, continue stirring 5 it is small when, after dichloromethane completely volatilization after, centrifuge microballoon, then use
Distilled water washs 5 times, is placed in pre-freeze 12h in -80 DEG C of refrigerators, then be placed in freeze drier and be freeze-dried, and obtains magnesium granules/poly-
(Pfansteihl) microballoon composite material.
Embodiment 4：
0.27g poly (L-lactic acid) is weighed, is dissolved in 5mL dichloromethane solvents, is configured to the solution that concentration is 54g/L.Treat
After it is completely dissolved, then 0.03g magnesium granules (31.02 ± 14.17 μm of average grain diameter) are accurately weighed, be added thereto and fully stir
Mix, magnesium is dispersed in solution, obtain oil phase.25mg bovine serum albumins are weighed as model drug, are dissolved in 0.5mL deionized waters
In, the solution that concentration is 50g/L is configured to, obtains inner aqueous phase.2.5g polyvinyl alcohol is weighed, is dissolved in 250mL deionized waters, is configured
Into the solution that concentration is 10g/L, outer aqueous phase is obtained.Inner aqueous phase is poured into oil phase, the Probe Ultrasonic Searching 30s under condition of ice bath, every time
Ultrasonic 2.5s pauses 0.5s, obtains W/O (Water-In-Oil) colostrum.Outer aqueous phase is placed in high speed agitator again, with the speed of 550rpm
It is stirred, W/O (Water-In-Oil) colostrum is instilled in the outer aqueous phase of high-speed stirred dropwise with rubber head dropper, obtains W/O/W (oil-in-waters
Bao Shui) emulsion, continue stirring 5 it is small when, after dichloromethane completely volatilization after, centrifuge microballoon, then wash 5 with distilled water
Time, pre-freeze 12h in -80 DEG C of refrigerators is placed in, then be placed in freeze drier and be freeze-dried, obtain magnesium granules/poly (L-lactic acid) microballoon
Composite material.
Embodiment 5：
0.27g Poly(D,L-lactide-co-glycolides (PLGA) are weighed, is dissolved in 5mL dichloromethane solvents, is configured to concentration
For the solution of 54g/L.After it is completely dissolved, then 0.03g magnesium granules (9.67 ± 4.93 μm of average grain diameter) are accurately weighed, added
Wherein and it is sufficiently stirred, magnesium is dispersed in solution, obtains oil phase.25mg bovine serum albumins are weighed as model drug, are dissolved in
In 0.5mL deionized waters, the solution that concentration is 50g/L is configured to, obtains inner aqueous phase.2.5g polyvinyl alcohol is weighed, 250mL is dissolved in and goes
In ionized water, the solution that concentration is 10g/L is configured to, obtains outer aqueous phase.Inner aqueous phase is poured into oil phase, is popped one's head under condition of ice bath
Ultrasonic 30s, each ultrasound 2.5s pause 0.5s, obtains W/O (Water-In-Oil) colostrum.Outer aqueous phase is placed in high speed agitator again, with
The speed of 550rpm is stirred, and is instilled in the outer aqueous phase of high-speed stirred W/O (Water-In-Oil) colostrum dropwise with rubber head dropper, is obtained
W/O/W (W/O/W) emulsion, continue stirring 5 it is small when, after dichloromethane completely volatilization after, centrifuge microballoon, then use
Distilled water washs 5 times, is placed in pre-freeze 12h in -80 DEG C of refrigerators, then is placed in freeze drier and is freeze-dried, and obtains magnesium granules/PLGA
Microballoon composite material.
Embodiment 6：
0.3g poly (L-lactic acid) is weighed, is dissolved in 5mL dichloromethane solvents, is configured to the solution that concentration is 60g/L.Treat it
After being completely dissolved, 25mg aspirin is weighed as model drug, is dissolved in wherein, then accurately weigh 0.03g magnesium granules (average grain diameters
9.67 ± 4.93 μm), it is added thereto and is sufficiently stirred, magnesium is dispersed in solution.Then, this solution is cast in culture
In ware, pre-freeze 12h in -80 DEG C of refrigerators is placed in, then be placed in freeze drier and be freeze-dried.Material after finally will be lyophilized is placed in
Tabletting in tablet press machine, obtains magnesium granules/poly (L-lactic acid) film composite material.
Embodiment 7：
Weigh 0.6g poly (L-lactic acid), be dissolved in 7.5mL Isosorbide-5-Nitraes-dioxane, be stirred at room temperature 4-6 it is small when, configuration
Into the solution that concentration is 80g/L.After it is completely dissolved, then weigh 25mg aspirin and 150mg magnesium granules are added thereto, and
It is uniformly mixed.This mixed solution is slowly cast in tubulose polystyrene mould, and mould is stayed overnight as at -20 DEG C.
Then, the composite material after abundant freezing is removed into organic solvent therein, up to magnesium as 48h is freezed in freeze drier
Particle/poly (L-lactic acid) prop composite.
Claims (10)
- A kind of 1. composite material using degradable metal Grain size controlling insoluble drug release, it is characterised in that the composite material by High molecular polymer, degradable metal particle and medicine composition.
- 2. composite material according to claim 1, it is characterised in that the high molecular polymer is that degradable macromolecule gathers Compound.
- 3. composite material according to claim 1, it is characterised in that the high molecular polymer is non-degradable macromolecule Polymer.
- 4. composite material according to claim 1, it is characterised in that the degradable metal particle refer to can using water as The metallic particles degraded in the environment of medium.
- 5. composite material according to claim 1, it is characterised in that the degradable metal particle is iron particle, magnesium Grain or zinc particle.
- 6. composite material according to claim 1, it is characterised in that in the composite material medicine be released through adjusting can The quantity and/or size and/or species of degraded metallic particles are controlled.
- 7. composite material according to claim 1, it is characterised in that the composite material is that microballoon composite material, film are multiple Condensation material or prop composite.
- It is 8. a kind of compound using degradable metal particle/high molecular polymer microballoon of degradable metal Grain size controlling insoluble drug release The preparation method of material, it is characterised in that the preparation of the microballoon composite material is first by high molecular polymer, degradable gold Metal particles and medicine are sufficiently mixed, and then high speed emulsion dispersion forms under the action of surfactant.
- A kind of 9. degradable metal particle/polymer membrane composite wood using degradable metal Grain size controlling insoluble drug release The preparation method of material, it is characterised in that the preparation process of the film composite material is first by high molecular polymer, degradable gold Metal particles and medicine are sufficiently mixed obtained mixed liquor, and then this mixed liquor is cast in culture dish, and are freeze-dried, then with pressure Piece machine tabletting is made.
- 10. a kind of answered using degradable metal particle/high molecular polymer stent of degradable metal Grain size controlling insoluble drug release The preparation method of condensation material, it is characterised in that the preparation of the prop composite be first by high molecular polymer, it is degradable Metallic particles and medicine are sufficiently mixed obtained mixed liquor, and then this mixed liquor is cast in polystyrene mould, then low temperature cold But, freeze-drying forms.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810068594.8A CN107998108A (en) | 2018-01-24 | 2018-01-24 | A kind of composite material using degradable metal Grain size controlling insoluble drug release |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810068594.8A CN107998108A (en) | 2018-01-24 | 2018-01-24 | A kind of composite material using degradable metal Grain size controlling insoluble drug release |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107998108A true CN107998108A (en) | 2018-05-08 |
Family
ID=62066389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810068594.8A Pending CN107998108A (en) | 2018-01-24 | 2018-01-24 | A kind of composite material using degradable metal Grain size controlling insoluble drug release |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107998108A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112386748A (en) * | 2019-08-12 | 2021-02-23 | 湖南早晨纳米机器人有限公司 | Magnesium alloy nano robot and preparation method thereof |
| CN112391599A (en) * | 2019-08-12 | 2021-02-23 | 湖南早晨纳米机器人有限公司 | Magnesium alloy sputtering nano robot and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1604697A1 (en) * | 2004-06-09 | 2005-12-14 | J.A.C.C. GmbH | Implantable device |
| CN101309653A (en) * | 2005-11-15 | 2008-11-19 | 奥巴斯尼茨医学公司 | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
| CN106236699A (en) * | 2016-08-25 | 2016-12-21 | 中国医科大学附属第医院 | A kind of antitumor sustained-release implant and preparation method thereof |
| CN107519539A (en) * | 2017-09-11 | 2017-12-29 | 乐普（北京）医疗器械股份有限公司 | A kind of medical degradable Zn-base alloy and its intravascular stent product |
-
2018
- 2018-01-24 CN CN201810068594.8A patent/CN107998108A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1604697A1 (en) * | 2004-06-09 | 2005-12-14 | J.A.C.C. GmbH | Implantable device |
| CN101309653A (en) * | 2005-11-15 | 2008-11-19 | 奥巴斯尼茨医学公司 | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
| CN106236699A (en) * | 2016-08-25 | 2016-12-21 | 中国医科大学附属第医院 | A kind of antitumor sustained-release implant and preparation method thereof |
| CN107519539A (en) * | 2017-09-11 | 2017-12-29 | 乐普（北京）医疗器械股份有限公司 | A kind of medical degradable Zn-base alloy and its intravascular stent product |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112386748A (en) * | 2019-08-12 | 2021-02-23 | 湖南早晨纳米机器人有限公司 | Magnesium alloy nano robot and preparation method thereof |
| CN112391599A (en) * | 2019-08-12 | 2021-02-23 | 湖南早晨纳米机器人有限公司 | Magnesium alloy sputtering nano robot and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mai et al. | Electrospray biodegradable microcapsules loaded with curcumin for drug delivery systems with high bioactivity | |
| US3773919A (en) | Polylactide-drug mixtures | |
| Sah et al. | Biodegradable microcapsules prepared by aw/o/w technique: effects of shear force to make a primary w/o emulsion on their morphology and protein release | |
| KR20110075618A (en) | Injectable porous microparticle filler system | |
| CN109998997B (en) | Method for preparing polyester organic polymer microspheres by using membrane emulsification method | |
| CN107998108A (en) | A kind of composite material using degradable metal Grain size controlling insoluble drug release | |
| CN106421800A (en) | Silk fibroin modified depression structure lactic acid-based polymer drug-carrying microsphere and method for preparing same | |
| CN104689323A (en) | Oil-soluble drug microsphere with slow release function and preparation method thereof | |
| CN108743545A (en) | A kind of alginate-drug-carrying nanometer particle-polycation microcapsules and its preparation and application | |
| CN109010307A (en) | Carry narcotic analgesics sustained-release micro-spheres, preparation method and its application | |
| CN104886091B (en) | A kind of biodegradable emamectin-benzoate microballoon | |
| CN105596298B (en) | A kind of PEG-PLGA sustained-release micro-spheres and preparation method thereof containing buprenorphine | |
| CN108451925A (en) | It is a kind of to be used to carry hollow sustained-release micro-spheres of medicine and preparation method thereof | |
| CN107138103A (en) | A kind of antibacterial complex microsphere of polycaprolactone/berberine and preparation method thereof | |
| CN104288111A (en) | Ginsenoside Rg3 poly(lactic-co-glycolic acid) nano microsphere and preparation method thereof | |
| CN109529126A (en) | A kind of artificial dermis and preparation method thereof | |
| CN110367249A (en) | A kind of degradable medicine carrying membrane material and its preparation method and application with slow-release function step by step | |
| CN104013568A (en) | Preparation method of chitosan microcapsule/starch composite membrane for drug sustained release | |
| CN103462902B (en) | There is the preparation method of hierarchy and fabric of island-in-sea type pattern PLGA/PCL complex microsphere | |
| CN105395487B (en) | A kind of double injection system preparing degradable polymer supported medicine microballoon | |
| CN102068948A (en) | Polymer microsphere with golf ball surface structure and preparation method thereof | |
| JP7266220B2 (en) | Microsphere sustained-release injection containing escitalopram and method for producing the same | |
| CN116492509A (en) | Filler for medical shaping and preparation method thereof | |
| CN103599075A (en) | Sustained release microspheres of polyethylene glycol-polylactic acid entrapped betamethasone dipropionate and preparation method thereof | |
| RU2209060C2 (en) | Method for obtaining membrane-covered spherical granules of prostane |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180508 |